These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 32961077)
1. Contemplating HPV vaccination in Japan during the time of COVID-19. Miyoshi A; Ueda Y; Kimura T Hum Vaccin Immunother; 2021 Mar; 17(3):836-837. PubMed ID: 32961077 [TBL] [Abstract][Full Text] [Related]
2. Human Papillomavirus Vaccination After COVID-19. Toh ZQ; Russell FM; Garland SM; Mulholland EK; Patton G; Licciardi PV JNCI Cancer Spectr; 2021 Apr; 5(2):pkab011. PubMed ID: 33748668 [TBL] [Abstract][Full Text] [Related]
3. The European response to the WHO call to eliminate cervical cancer as a public health problem. Arbyn M; Gultekin M; Morice P; Nieminen P; Cruickshank M; Poortmans P; Kelly D; Poljak M; Bergeron C; Ritchie D; Schmidt D; Kyrgiou M; Van den Bruel A; Bruni L; Basu P; Bray F; Weiderpass E Int J Cancer; 2021 Jan; 148(2):277-284. PubMed ID: 32638362 [TBL] [Abstract][Full Text] [Related]
4. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ; MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109 [TBL] [Abstract][Full Text] [Related]
5. No Vacillation on HPV Vaccination. Sipp D; Frazer IH; Rasko JEJ Cell; 2018 Mar; 172(6):1163-1167. PubMed ID: 29522737 [TBL] [Abstract][Full Text] [Related]
6. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. Cody P; Tobe K; Abe M; Elbasha EH BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of human papillomavirus vaccination in young Japanese women: a retrospective multi-municipality study. Tozawa-Ono A; Kamada M; Teramoto K; Hareyama H; Kodama S; Kasai T; Iwanari O; Koizumi T; Ozawa N; Suzuki M; Kinoshita K Hum Vaccin Immunother; 2021 Apr; 17(4):950-954. PubMed ID: 33121340 [TBL] [Abstract][Full Text] [Related]
8. The last strategy for re-dissemination of HPV vaccination in Japan while still under the suspension of the governmental recommendation. Ueda Y; Yagi A; Abe H; Nakagawa S; Minekawa R; Kuroki H; Miwa A; Kimura T Sci Rep; 2020 Sep; 10(1):16091. PubMed ID: 32999408 [TBL] [Abstract][Full Text] [Related]
9. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation. Larson HJ; Wilson R; Hanley S; Parys A; Paterson P Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472 [TBL] [Abstract][Full Text] [Related]
10. Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan. Nakagawa S; Ueda Y; Yagi A; Ikeda S; Hiramatsu K; Kimura T Cancer Sci; 2020 Jun; 111(6):2156-2162. PubMed ID: 32248632 [TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus vaccine: widening the scope for cancer prevention. No JH; Kim MK; Jeon YT; Kim YB; Song YS Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574 [TBL] [Abstract][Full Text] [Related]
12. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook. Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782 [TBL] [Abstract][Full Text] [Related]
13. A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation. Ishimoto T; Yagi A; Nakajima K; Okamoto N; Yukimitsu E; Kawasaki M; Kawae Y; Hayasaka S; Ueda Y; Kimura T Hum Vaccin Immunother; 2023 Aug; 19(2):2229222. PubMed ID: 37462048 [TBL] [Abstract][Full Text] [Related]
14. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. Arbyn M; Dillner J J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503 [TBL] [Abstract][Full Text] [Related]
15. Beneficial Effects of Human Papillomavirus Vaccine for Prevention of Cervical Abnormalities in Miyagi, Japan. Ozawa N; Ito K; Tase T; Metoki H; Yaegashi N Tohoku J Exp Med; 2016 Oct; 240(2):147-151. PubMed ID: 27746423 [TBL] [Abstract][Full Text] [Related]
16. Educational intervention for women in Japan coming of age for cervical cancer screening who grew up during the suspended HPV-vaccination-program. Miyoshi A; Ueda Y; Yagi A; Kimura T; Kobayashi E; Hiramatsu K; Nakagawa S; Kimura T Hum Vaccin Immunother; 2021 Nov; 17(11):4418-4422. PubMed ID: 35016492 [TBL] [Abstract][Full Text] [Related]
17. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination. Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan. Yagi A; Nakagawa S; Ueda Y; Oka E; Ikeda S; Kakuda M; Kobayashi E; Ito Y; Katayama K; Hirai K; Nakayama T; Kimura T Cancer Sci; 2024 Mar; 115(3):916-925. PubMed ID: 38158850 [TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of vaccination against HPV in Israel. Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844 [TBL] [Abstract][Full Text] [Related]
20. HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives. Yagi A; Ueda Y; Kimura T Vaccine; 2024 Sep; 42(22):125859. PubMed ID: 38616440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]